The Economics of Malaria Vaccine Development. Issue 3 (March 2017)

• Record Type: Journal Article
• Authors: Plebanski, Magdalena; Flanagan, Katie L.
• Is Part Of: Trends in parasitology. Volume 33:Issue 3(2017:Mar.)
• Page Start: 154
• Page End: 156
• Publication Date: 2017-03
• Subjects: Parasitology -- Periodicals; Parasitology -- Periodicals; Biology -- Periodicals; Parasitology; Biology; Parasitologie -- Périodiques; Online resources; 571.999
• DOI: 10.1016/j.pt.2017.01.006
• Languages: English
• ISSNs: 1471-4922

Abstract

Abstract : Vaccines that do not take a comprehensive endpoint view of the pathogen population they want to tackle early in their developmental process, may find it financially prohibitive to redesign them once they have progressed down a costly regulatory and human trial pathway. Specifically, the lead malaria vaccine candidate RTS, S has limited ability to tackle parasite polymorphism and may induce sex-specific nonspecific effects (NSEs).